Michael Barbella, Managing Editor02.06.23
A solid future is forecast for the global orthobiologics market.
Research Nester preducts the sector will expand 6% annually through 2033 due to the increasing prevalence of bone diseases worldwide. National Library of Medicine (NLM) data indicates that nearly 1.5 million people suffer from bone disease-related fractures every year. Orthobiologics have become a common practice in orthopedic operations and sports medicineof late. An increase in sports injuries, new products and treatment options, regenerative medicine developments, and rising demand for minimally invasive operations are all expected to contribute to the market's growth over the next 10 years.
Orthobiologics is an injectable therapy that uses biological substances to rapidly heal musculoskeletal injuries. Substances used in the therapy are made from materials naturally produced by the body. the growing prevalence of low immunity and calcium deficiency, owing to changing lifestyles and skyrocketing spending in medtech R&D are projected to help the sector expand through 2033. In 2019, medtech R&D spending was estimated at $30 billion.
The market also will benefit from higher orthopedic device sales—an outgrowth of more bone fractures and bone infections globally. The orthopedic devices segment is estimated to be worth about $40 billion last year. Various technologies are embedded in orthobiologics devices to improve the functionality of the broken bone, and components including, scaffolds to reinforce tissue, cell therapies, and bone grafting materials are used in the therapy. All these components are predicted to boost market growth over the ensuing years.
Additionally, rising osteoporosis cases worldwide are likely to fuel the sector's expansion through 2033. One in two women and one in five men older than 50 suffer from osteoporosis globally and in 2017-18, around 18% of women were believed to be living with osteoporosis. The increasing prevalence of a low-calcium diet and growing penchant for fast food and junk food is expected to boost future osteoporosis rates.
The global orthobiologics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region. North America is forecast to hold the largest market share over the forecast period, and its growth can be attributed to the area's aging population and corresponding rising incidences of bone fractures and bone infection among the elderly people. The World Bank observed the U.S. geriatric population climbed by 56.5 million in 2021. Technological advancements and the presence of key market players also will help boost the market's growth in this region.
The Asia Pacific region will likely witness noteworthy growth due to rising osteoporosis cases. By 2050, Asia is expected to account for more than half of all osteoporotic hip fractures, according to research from the International Osteoporosis Foundation. The consumption of a low-calcium diet, rising prevalence of bone diseases, and high healthcare spending also will contribute to the sector's expansion.
The orthobiologics market is segmented by end user into clinics and hospitals. Of these, the hospitals segment is estimated to gain noteworthy market share through 2033 due to the increasing hospital patient pool globally. In 2019, about 7% of the U.S. population was hospitalized. A rising awareness among people about bone health, increasing medical advancements, and significant investments into healthcare infrastructure worldwide will also benefit the sector in the next decade.
The market is segmented by application into spinal fusion, trauma repair, and reconstructive surgery. Of these, the spinal fusion segment will gain considerable market share due to rising spinal cord injury cases globally. As Per World Health Organization, between 250,000 to 500,000 persons suffer a spinal cord injury (SCI) annually. The sector also is likely to benefit from the rise in sports-related spinal cord injuries.
Key orthobiologics market players include Medtronic plc, Wright Medical Group N.V., Zimmer Biomet Holdings Inc., Arthrex Inc., Medical Device Business Services Inc., Johnson & Johnson, RTI Surgical Inc., MTG Learning Media Pvt. Ltd., Bioventus LLC, Stryker Corporation, and others.
Research Nester preducts the sector will expand 6% annually through 2033 due to the increasing prevalence of bone diseases worldwide. National Library of Medicine (NLM) data indicates that nearly 1.5 million people suffer from bone disease-related fractures every year. Orthobiologics have become a common practice in orthopedic operations and sports medicineof late. An increase in sports injuries, new products and treatment options, regenerative medicine developments, and rising demand for minimally invasive operations are all expected to contribute to the market's growth over the next 10 years.
Orthobiologics is an injectable therapy that uses biological substances to rapidly heal musculoskeletal injuries. Substances used in the therapy are made from materials naturally produced by the body. the growing prevalence of low immunity and calcium deficiency, owing to changing lifestyles and skyrocketing spending in medtech R&D are projected to help the sector expand through 2033. In 2019, medtech R&D spending was estimated at $30 billion.
The market also will benefit from higher orthopedic device sales—an outgrowth of more bone fractures and bone infections globally. The orthopedic devices segment is estimated to be worth about $40 billion last year. Various technologies are embedded in orthobiologics devices to improve the functionality of the broken bone, and components including, scaffolds to reinforce tissue, cell therapies, and bone grafting materials are used in the therapy. All these components are predicted to boost market growth over the ensuing years.
Additionally, rising osteoporosis cases worldwide are likely to fuel the sector's expansion through 2033. One in two women and one in five men older than 50 suffer from osteoporosis globally and in 2017-18, around 18% of women were believed to be living with osteoporosis. The increasing prevalence of a low-calcium diet and growing penchant for fast food and junk food is expected to boost future osteoporosis rates.
The global orthobiologics market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa region. North America is forecast to hold the largest market share over the forecast period, and its growth can be attributed to the area's aging population and corresponding rising incidences of bone fractures and bone infection among the elderly people. The World Bank observed the U.S. geriatric population climbed by 56.5 million in 2021. Technological advancements and the presence of key market players also will help boost the market's growth in this region.
The Asia Pacific region will likely witness noteworthy growth due to rising osteoporosis cases. By 2050, Asia is expected to account for more than half of all osteoporotic hip fractures, according to research from the International Osteoporosis Foundation. The consumption of a low-calcium diet, rising prevalence of bone diseases, and high healthcare spending also will contribute to the sector's expansion.
The orthobiologics market is segmented by end user into clinics and hospitals. Of these, the hospitals segment is estimated to gain noteworthy market share through 2033 due to the increasing hospital patient pool globally. In 2019, about 7% of the U.S. population was hospitalized. A rising awareness among people about bone health, increasing medical advancements, and significant investments into healthcare infrastructure worldwide will also benefit the sector in the next decade.
The market is segmented by application into spinal fusion, trauma repair, and reconstructive surgery. Of these, the spinal fusion segment will gain considerable market share due to rising spinal cord injury cases globally. As Per World Health Organization, between 250,000 to 500,000 persons suffer a spinal cord injury (SCI) annually. The sector also is likely to benefit from the rise in sports-related spinal cord injuries.
Key orthobiologics market players include Medtronic plc, Wright Medical Group N.V., Zimmer Biomet Holdings Inc., Arthrex Inc., Medical Device Business Services Inc., Johnson & Johnson, RTI Surgical Inc., MTG Learning Media Pvt. Ltd., Bioventus LLC, Stryker Corporation, and others.
